Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

ARCT Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $8.81M fell 22.2% year over year, behind the -11.6% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 37.2% from the prior quarter. Over 3 fiscal years it compounded at +0.0% a year.

Context

  • Selling, general & admin amounted to 68.5% of revenue in FY2025, up 30.4 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 8 analysts of $25.77M (-44.1%) for the fiscal year ending Dec 2026, a slowdown from the -12.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.81M-37.2% QoQ
Last fiscal yearDec 2025
$46.08M-12.8% YoY
LTMMar 2026
$43.57M-11.6% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.2%-70.1%-47.9 pp
1 year-12.8%-44.1%-31.3 pp
3-year CAGR+0.0%-1.6%-1.6 pp
5-year CAGR+48.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
46.08M USD
Year-over-year change
-12.8%
4-year CAGR
+2.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ARCT compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -11.6% is the 4th highest of 9, against a peer median of -26.5%.
  • Selling, general & admin amounts to 96.1% of revenue for ARCT, versus a peer median of 75.4%.
ARCT Competitors
Selling, General & Admin for ARCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$16.46B USD+48531.9%-28.7%—
NVAXNovavax, Inc.LTM Mar 2026$127.98M USD-57.1%-32.5%21.5%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$75.11M USD-30.1%+13.7%—
VALNValneva SELTM Mar 2026€70.46M EUR-23.0%+9.1%45.1%
VIRVir Biotechnology, Inc.LTM Mar 2026$69.19M USD——105.6%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$43.57M USD-11.6%+0.0%96.1%
BNTCBenitec Biopharma Inc.LTM Mar 2026$34.74M USD+87.8%+52.2%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$30.28M USD-34.0%-12.3%—
SLNSilence Therapeutics plcLTM Mar 2026$23.59M USD—+2.2%2560.2%
ABUSArbutus Biopharma CorporationLTM Mar 2026$15.94M USD-39.5%-3.8%8.3%
PRQRProQR Therapeutics N.V.LTM Mar 2026€14.33M EUR+6.6%-8.9%106.6%
Peer median (excluding ARCT) —-26.5%-3.8%75.4%

Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.36M205.76M157.75M138.39M67.22M
Cost of Revenue00003.03M
Gross Profit12.36M205.76M157.75M138.39M64.2M
Gross Margin100.0%100.0%100.0%100.0%95.5%
Research & Development173.76M147.75M192.13M195.16M112.21M
Selling, General & Admin41.45M46.07M52.87M52.82M46.08M
Operating Expenses215.21M193.58M235.95M234.06M139.15M
Depreciation & Amortization1.19M1.53M2.96M3.54M3.03M
EBITDA(199.81M)15.17M(24.17M)(77.4M)(62.76M)
EBITDA Margin-1616.7%7.4%-15.3%-55.9%-93.4%
Operating Income(202.85M)12.18M(78.21M)(95.67M)(74.96M)
Operating Margin-1641.3%5.9%-49.6%-69.1%-111.5%
Interest Income753K2.58M17.36M15.2M10.1M
Interest Expense2.67M3M767K00
Other Income / Expenses(822K)(1.53M)50.32M14.72M9.17M
Income Before Tax(203.67M)10.64M(27.89M)(80.95M)(65.78M)
Pre-Tax Margin-1648.0%5.2%-17.7%-58.5%-97.9%
Income Tax Expense01.3M1.84M(4K)0
Net Income(203.67M)9.35M(29.73M)(80.94M)(65.78M)
Net Margin-1648.0%4.5%-18.8%-58.5%-97.9%
EPS (Basic)(7.74)0.35(1.12)(3.00)(2.40)
EPS (Diluted)(7.74)0.35(1.12)(3.00)(2.40)
Weighted Avg Shares26.32M26.45M26.63M27M27.39M
Weighted Avg Shares (Diluted)26.32M27.09M26.63M27M27.39M

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Intrinsic Alpha fair value

Locked

Current Price

$8.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.